文献速递慢性肾脏病

非糖尿病CKD患者白蛋白尿严重程度与心血管及肾脏结局:CRIC研究

Cardiovascular and Kidney Outcomes of Non-Diabetic CKD by Albuminuria Severity: Findings From the CRIC Study.
PubMed 文献 · Am J Kidney Dis · 2024-07-19

本研究基于CRIC前瞻性队列中1463例非糖尿病CKD患者,按尿白蛋白水平分组,评估肾脏与心血管结局。结果显示,与正常白蛋白尿相比,中度和重度白蛋白尿患者的肾脏复合结局风险显著升高(AHR分别为3.3和8.6),心血管结局风险也升高(AHR均为1.5)。正常白蛋白尿患者eGFR下降速度最慢,但心血管事件风险仅略低于高白蛋白尿者,且心血管事件风险远高于肾脏疾病进展风险。

要点

  • 非糖尿病CKD患者中,白蛋白尿水平越高,肾脏复合结局风险越高。
  • 正常白蛋白尿患者eGFR下降速度最慢,但心血管事件风险仍较高。
  • 低白蛋白尿患者心血管事件风险远高于肾脏疾病进展风险。

核心结论

  • 非糖尿病CKD患者中,正常白蛋白尿者肾脏进展显著更慢,但心血管风险仅略低于高白蛋白尿者。

研究设计与样本

  • 前瞻性队列研究,纳入1463例无已知肾小球肾炎的非糖尿病CKD成人,诊断为高血压肾硬化或病因不明。

主要发现

  • 与正常白蛋白尿相比,中度白蛋白尿肾脏复合结局AHR为3.3(95%CI 2.4-4.6),重度为8.6(95%CI 6.0-12.0)。
  • 与正常白蛋白尿相比,中度白蛋白尿心血管复合结局AHR为1.5(95%CI 1.2-1.9),重度为1.5(95%CI 1.1-2.0)。
  • 正常白蛋白尿(<30μg/mg,n=863)eGFR年下降0.46mL/min/1.73m2,中度(30-300μg/mg,n=372)为1.41,重度(>300μg/mg,n=274)为2.63。
  • 肾脏结局平均发生时间:中度白蛋白尿8.6年,重度7.3年,正常白蛋白尿9.3年。
  • 心血管结局平均发生时间在三组间相似(分别为8.2、8.1、8.6年)。

临床怎么用

  • 对非糖尿病CKD患者,即使白蛋白尿正常,也应重视心血管风险评估与管理。
  • 白蛋白尿水平可用于分层预测肾脏进展速度,指导随访强度。

局限性

  • CKD病因基于自我报告,缺乏肾活检确认。
  • 存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The clinical trajectory of normoalbuminuric chronic kidney disease (CKD), particularly in the absence of diabetes, has not yet been well-studied. This study evaluated the association of kidney and cardiovascular outcomes with levels of albuminuria in a cohort of patients with nondiabetic CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 1,463 adults with nondiabetic CKD without known glomerulonephritis and diagnosed with hypertensive nephrosclerosis or unknown cause of CKD participating in the Chronic Renal Insufficiency Cohort (CRIC) Study. EXPOSURE: Albuminuria stage at study entry. OUTCOME: Primary outcome: Composite kidney (halving of estimated glomerular filtration rate [eGFR], kidney transplantation, or dialysis), Secondary outcomes: (1) eGFR slope, (2) composite cardiovascular disease events (hospitalization for heart failure, myocardial infarction, stroke, or all-cause death), (3) all-cause death. ANALYTICAL APPROACH: Linear mixed effects and Cox proportional hazards regression analyses. RESULTS: Lower levels of albuminuria were associated with female sex and older age. For the primary outcome, compared with normoalbuminuria, those with moderate and severe albuminuria had higher rates of kidney outcomes (adjusted hazard ratio [AHR], 3.3 [95% CI, 2.4-4.6], and AHR, 8.6 [95% CI, 6.0-12.0], respectively) and cardiovascular outcomes (AHR, 1.5 [95% CI, 1.2-1.9], and AHR, 1.5 [95% CI, 1.1-2.0], respectively). Those with normoalbuminuria (<30μg/mg; n=863) had a slower decline in eGFR (-0.46mL/min/1.73m2 per year) compared with those with moderate (30-300μg/mg, n=372; 1.41mL/min/1.73m2 per year) or severe albuminuria (>300μg/mg, n=274; 2.63mL/min/1.73m2 per year). In adjusted analyses, kidney outcomes occurred, on average, sooner among those with moderate (8.6 years) and severe (7.3 years) albuminuria compared with those with normoalbuminuria (9.3 years) whereas the average times to cardiovascular outcomes were similar across albuminuria groups (8.2, 8.1, and 8.6 years, respectively). LIMITATIONS: Self-report of CKD etiology without confirmatory kidney biopsies; residual confounding. CONCLUSIONS: Participants with normoalbuminuric nondiabetic CKD experienced substantially slower CKD progression but only modestly lower cardiovascular risk than those with high levels of albuminuria. These findings inform the design of future studies investigating interventions among individuals with lower levels of albuminuria. PLAIN-LANGUAGE SUMMARY: Diabetes and hypertension are the leading causes of chronic kidney disease (CKD). Urine albumin levels are associated with cardiovascular and kidney disease outcomes among individuals with CKD. However, previous studies of long-term clinical outcomes in CKD largely included patients with diabetes. As well, few studies have evaluated long-term outcomes across different levels of urine albumin among people without diabetes. In this study, we found individuals with nondiabetic CKD and low urine albumin had much slower decline of kidney function but only a modestly lower risk of a cardiovascular events compared with those with high levels of urine albumin. Individuals with low urine albumin were much more likely to have a cardiovascular event than progression of their kidney disease. These findings inform the design of future studies investigating treatments among individuals with lower levels of albuminuria.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Shulman R, Yang W, Cohen DL, et al. Cardiovascular and Kidney Outcomes of Non-Diabetic CKD by Albuminuria Severity: Findings From the CRIC Study. Am J Kidney Dis. 2024. PMID: 39032679. doi:10.1053/j.ajkd.2024.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。